Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marizu Borrego

Physician Assistant San Antonio, TX Physician Assistant

NPI 1003041666 CMS profile 10820528

19272 Stone Oak Pkwy, Suite 101, San Antonio, TX 78258

Open in the dashboard

General payments

$12,198

532 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marizu Borrego of San Antonio, TX is reported in the CMS Open Payments database as having received $12,198 across 532 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,062 126
2024 General $2,678 114
2023 General $2,661 113
2022 General $1,887 87
2021 General $1,910 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marizu Borrego
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Marizu Borrego were reported at $3,062. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Marizu Borrego Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,910 $132 $37–$438 $132
2022 $1,887 $155 $48–$522 $149
2023 $2,661 $167 $52–$557 $160
2024 $2,678 $178 $55–$600 $164
2025 $3,062 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $2,671 132 payments
  2. Janssen Biotech, Inc. $1,674 66 payments
  3. Novartis Pharmaceuticals Corporation $1,003 48 payments
  4. UCB, Inc. $816 28 payments
  5. Lilly USA, LLC $717 30 payments
  6. Mallinckrodt Hospital Products Inc. $622 25 payments
  7. Genentech USA, Inc. $597 35 payments
  8. GlaxoSmithKline, LLC. $593 34 payments
  9. AstraZeneca Pharmaceuticals LP $460 21 payments
  10. Pfizer Inc. $444 28 payments
  11. Other $2,600 85 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,108 531 payments
  2. Education $90 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $1,491 57 payments
  2. Otezla $989 49 payments
  3. COSENTYX $941 45 payments
  4. SIMPONI ARIA $829 30 payments
  5. Enbrel Inflammation $741 36 payments
  6. Enbrel Inflammation $655 36 payments
  7. ACTHAR $622 25 payments
  8. TALTZ $607 29 payments
  9. BENLYSTA $593 34 payments
  10. Cimzia $554 18 payments
  11. Other $6,123 289 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

602

Median for Physician Assistant: 241

Drug cost

$622,477

Median for Physician Assistant: $4,110

Branded share of claims

30.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 16 $162,621
Humira(Cf) Adalimumab Brand 11 $149,857
Taltz Autoinjector Ixekizumab Brand 13 $88,901
Taltz Syringe Ixekizumab Brand 12 $79,918
Simponi Golimumab Brand 12 $68,195
Actemra Tocilizumab Brand 13 $62,308
Mycophenolate Mofetil Generic 27 $2,743
Hydroxychloroquine Sulfate Generic 107 $2,210
Methotrexate Methotrexate Sodium Brand 75 $1,523
Sulfasalazine Dr Sulfasalazine Brand 30 $1,006

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $296
  • Janssen Scientific Affairs, LLC $100
$396 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $359
$359 — —
KRYSTEXXA
  • Amgen Inc. $223
$223 — —
Enbrel
  • Amgen Inc. $199
$199 — —
Cimzia
  • UCB, Inc. $176
$176 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

532 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record